Subscribe

Biocompounding

Biocompounding

Thank you for your support in 2022

Thank you for your support in 2022

Dear Readers, We would like to thank everyone who has supported us in our journey in 2022. We started this newsletter in June 2022 and have seen steady growth in the past 6 months. When we started 6 months back, we were unsure what the demand would be for life

Can Precision Fermentation together with Synthetic Biology Help to Secure Our Food Systems?

Can Precision Fermentation together with Synthetic Biology Help to Secure Our Food Systems?

The recent geopolitical tensions and climate change have brought our food system under strain forcing governments to limit exports to protect their citizens. These issues have led to discussions around finding alternative protein sources and ensure food systems are inclusive, efficient and sustainable. Globally, in 2020, humans consumed 574 million

Why Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is a biotech force to be reckoned with

Regeneron was founded in 1988 by Dr. Leonard S Schleifer. Dr. Schelifer shared, that the name Regeneron came from “Regenerating neurons, with the word “gene” in the middle”. The origin of the name further explains that the initial focus of the company was neurobiology. Then in 1990 following the publication

5 Blockbuster Drugs Which Can Be Spun Out as a Company

5 Blockbuster Drugs Which Can Be Spun Out as a Company

Not all drugs are equal. While most pharmaceutical companies talk about their pipeline programs. Some drugs alone could be pharmaceutical/biotech and still have a robust pipeline. These drugs are usually targeting systemic pathways, enabling their use across multiple disease indications and in the process creating a pipeline for themselves.

Are RSV vaccines going to be the next blockbuster vaccine to be developed?

Are RSV vaccines going to be the next blockbuster vaccine to be developed?

The below graph shows that the rate of RSV-associated hospitalizations has increased significantly after the COVID pandemic (2020-2021 season). In the 2022-2023 season, the current estimate for RSV-associated hospitalization stood at 18 per 100k people in the US. However, this is just the start of the

Investing Basics 101: 3 Essential Guidelines for Asset Allocation

Investing Basics 101: 3 Essential Guidelines for Asset Allocation

Asset allocation is one of the first decisions to need to make when building a portfolio that suits your needs and goals; when you need the money essentially dictates where to invest it. As such, there’s no one-size-fits-all solution. Asset allocation should depend on factors such

Earnings Update for NVO, LLY & REGN

Earnings Update for NVO, LLY & REGN

1. Novo Nordisk (NVO) Novo reported a strong quarter as they continue to hold a dominant position in diabetes and obesity. Year to Date (9 months) results below: * Revenue: $128.8B (DKK +16%, US +21%, International +11%) * Op profit: $57.7B DKK +14% * Net profit: $41.9B * FCF: $62.5B